Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-28

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the safety and efficacy of Irinotecan Bead in the neoadjuvant treatment (i.e. the Irinotecan Bead is administered prior to surgery) of resectable liver metastases from colorectal cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer

NCT00816777

Unresectable Metastatic Colo-rectal Cancer

TERMINATED PHASE1/PHASE2

TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer

NCT01060423

Colorectal Cancer

TERMINATED PHASE2

Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer

NCT06341309

Metastatic Colorectal Cancer

NOT_YET_RECRUITING PHASE1/PHASE2

Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease

NCT04595266

Colorectal Cancer Metastatic Liver Metastasis Colon Cancer

ACTIVE_NOT_RECRUITING PHASE2

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

NCT06341296

Metastatic Colorectal Cancer

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Primary Endpoint of this study is Tumour resectability at surgery. Secondary Endpoints:

1. Safety assessed by SAE and AE monitoring (NCI CTCAE v3.0)
2. Tumour response assessed by imaging (RECIST and necrosis)
3. Viable residual tumour assessed by pathological evaluation of resected liver tissue.
4. Recurrence (time and site) following resection
5. Correlation of tumour response by imaging and pathology

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Irinotecan Bead

Group Type EXPERIMENTAL

Irinotecan Bead

Intervention Type DEVICE

Irinotecan eluting bead

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Irinotecan Bead

Irinotecan eluting bead

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Irinotecan Bead, PARAGON Bead

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Presence of potentially resectable colorectal cancer liver metastases, with less than 60% liver tumour replacement. The consulting surgeon, according to local practice, will determine resectability.
2. Patients having undergone complete resection of the primary tumour without gross or microscopic evidence of residual disease (R0), or the primary tumour is considered R0 resectable at screening.
3. Age: 18-80 years.
4. ECOG Status ≤2.
5. No previous irinotecan-containing chemotherapy for advanced disease.
6. Previous chemotherapy is allowed (unless it contained irinotecan), but must have ended at least one month prior to study entry.
7. Presence of adequate contraception in fertile (M/F) patients. Pregnant or lactating women are excluded.
8. Absence of any other previous malignancy other than adequately treated in situ carcinoma of the cervix or non-melanoma skin cancer (unless there has been a disease-free interval of at least 10 years).
9. Patients should not have participated in another clinical trial with any investigational drug in the 30 days prior to enrolment.
10. Absence of:

* Peripheral neuropathy (CTC \> grade 1)
* Uncontrolled congestive heart failure or angina pectoris, or hypertension or arrhythmia.
* History of significant neurologic or psychiatric disorders
* Active infection
11. Written informed consent according to ICH/EU GCP, and any applicable local, national or international regulations.
12. Patients with liver-dominant disease, defined as ≥80% of the tumour body burden confined to the liver. Unilobar disease, or bilobar disease suitable for treatment in a single chemoembolisation procedure, with a maximum of 4 lesions.
13. Hematologic function: WBC ≥3.0 x 10\*9/L, platelets ≥100 x 10\*9/L, Absolute neutrophil count \> 1.5 x 10\*9/l.
14. Adequate organ function as measured by:

1. Serum creatinine ≤2 x upper limit of normal (ULN).
2. Serum transaminases (AST \& ALT) ≤5 x ULN.
3. Total bilirubin ≤1.5 x ULN.
4. Prothrombin time \>50% of normal.

Exclusion Criteria

1. Extrahepatic metastases constituting \>20% of tumour body burden.
2. Contraindications to irinotecan:

1. Chronic inflammatory bowel disease and/or bowel obstruction.
2. History of severe hypersensitivity reactions to irinotecan hydrochloride trihydrate.
3. Severe bone marrow failure.
4. Concomitant use with St John's Wort.
3. Active bacterial, viral or fungal infection within 72 hours of study entry.
4. Allergy to contrast media that cannot be managed with standard care.
5. Any contraindication for hepatic embolisation procedures:

1. porto-systemic shunt.
2. hepatofugal blood flow.
3. severe atheromatosis.
6. Contraindication to hepatic artery catheterisation, such as a patient with severe peripheral vascular disease precluding catheterisation.
7. Other significant medical or surgical condition, or any medication or treatment regimens, that would place the patient at undue risk, that would preclude the safe use of chemoembolisation or would interfere with study participation.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No